About Policy Submissions

We regularly make submissions to national level inquiries. If you are after a submission from earlier than listed here, please contact us.

11 October 2021 Submission
CHF

The Australian Medical Research and Innovation Strategy (Strategy) is determined by the Australian Medical Research Advisory Board (AMRAB). The Strategy ensures a coherent and consistent approach is adopted in the funding of medical research and innovation from the Medical Research Future

...Read more
30 August 2021 Submission

This response advocates that the Australian Commission on Safety and Quality in Health Care (ASQHC) co-design the new Standards with consumers of mental health services.  This means not only consulting and engaging with consumers, but offering consumer led development of the...Read more

30 August 2021 Submission

CHF broadly supports the findings and recommendations of the findings and recommendations made in recent and previous years over many years. They confirm that consumers and carers experience a mental health system that fragmented, difficult to understand and navigate, and is not...Read more

26 August 2021 Submission
CHF

As a member of the Australian Bureau of Statistics (ABS) Health Statistics Advisory Group, CHF was asked to provide comment on a draft Privacy Impact Assessment (PIA) completed by Maddocks to inform the National Health Measures Study (NHMS) scheduled to...Read more

28 July 2021 Submission

The Primary Health Reform Steering Group was set up to advise the Government on developing the Primary Health Care 10 Year Plan. The Steering Group's discussion paper (...Read more

13 July 2021 Submission
CHF

On 25 February 2021, changes to the Therapeutic Goods (Medical Devices) Regulations 2002 (‘the Regulations’) commenced to introduce a new regulatory framework (the Framework) for medical devices that are designed and manufactured for individual patients (otherwise known as 'personalised' medical...Read more

18 June 2021 Submission
CHF

The Therapeutic Goods Advertising Code (No.2) 2018 (the Code) is the compliance standard that prescribes the minimum requirements for the lawful advertising of therapeutic goods to the public in Australia. It is an important instrument for a range of stakeholders including advertisers,...Read more

17 June 2021 Submission

CHF submitted this response to the House of Representatives Standing Committee on Health, Aged Care and Sport inquiry into approval processes for new drugs and novel medical technologies in Australia June 2021.

The recommendations, which include feedback from health consumers who are...Read more

29 March 2021 Submission
Consumers Health Forum

In 2015, the Report of the Expert Panel Review of Medicines and Medical Devices Regulation (MMDR) made 58 recommendations for reform of the regulatory framework for medicines and medical devices in Australia. The Australian Government Response to the Review of Medicines and Medical Devices...Read more

1 February 2021 Submission

CHF has provided this submission to the Commonwealth Government with recommendations for policy proposals and funding initiatives to be included in the 2021-22 Budget to improve health and wellbeing outcomes for Australian health consumers.

The submission draws on the work of...Read more

Pages